1132754-32-5

Basic information

• Product Name: 4-(ethylsulfonyl)-1-iodo-2-nitrobenzene
• CAS NO: 1132754-32-5
• Molecular Weight: 341.126
• Mol File: 1132754-32-5.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 4-(ethylsulfonyl)-1-iodo-2-nitrobenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(ethylsulfonyl)-1-iodo-2-nitrobenzene(1132754-32-5)
• EPA Substance Registry System: 4-(ethylsulfonyl)-1-iodo-2-nitrobenzene(1132754-32-5)

Safety Data

• Hazardous Substances Data: 1132754-32-5(Hazardous Substances Data)

Relevant articles and documents

Syntheses and In Vitro Anticancer Properties of Novel Radiosensitizers

Series of 4-(ethylsulfonyl)-1-halogen-2-nitrobenzene (3a-e) and 1-(4-halogen-3-nitrophenyl) propan-1-one (5a-d) analogs designed as novel radiosensitizers using bromonitropropiophenone and bromonitrobenzonitrile as lead compounds were synthesized. The anticancer activities of the compounds were evaluated in vitro using human prostate cancer (DU-145) and breast cancer (MCF-7) cell lines and the MTT assay. From the series, six compounds (3b-e, 5b-c) exhibited potent growth inhibitory effects against both cell lines. The most active, compound 3d, is an iodosulfone and is significantly more potent than the lead compound 5c at 10μm. Compounds were then compared with doxorubicin, a clinically used anticancer compound for breast and prostate cancers. Our most active compound 3d is more effective than doxorubicin at the dose level of 10μm at 3days after radiation, cell viabilities of 18%, 13% compared to 87%, 94% against MCF-7, and 15%, 20% compared to 60%, 75% against DU-145 without and with radiation, respectively. At 10μm, compound 5c had no effects as compared to control, whereas compound 3d reduced DU-145 cell viability to 16% and that of MCF-7 cells to 9% even at 5days after radiation. These results are very encouraging. Future studies include testing the compounds in vivo with and without radiation. Our most active compound 3d is significantly more effective than doxorubicin or lead compound 5c at the dose level of 10μm, without and with radiation; and in MCF-7 and DU-145 cell lines. These results are very encouraging. Future studies include testing the compounds in vivo without and with radiation.

NOVEL COMPOUNDS FOR TREATMENT OF MALIGNANT TUMORS

The present invention comprises compounds, compositions and methods of use for sensitizing cancer cells, tumors, neoplasms, and malignancies to the effects of ionizing radiation used in the treatment of cancer. The invention further comprises a method of identifying novel radiosensitizing compounds.